-Caroline Knapp, mother of a young kidney transplant patient
To better serve pediatric patients, the elderly, and other vulnerable populations, leaders in healthcare are looking for an alternative to venipuncture. They're discovering the revolutionary capabilities of breakthrough Volumetric Absorptive Microsampling (VAMS®) technology - a smarter blood collection system using Mitra® devices to streamline clinical processes, improve the patient experience, and generate gold-standard data.
Now it's your turn! Download these case studies to see how large and small organizations use microsampling technology as a more convenient and comfortable next-generation dried blood spot.
|
|
~Dr. Christophe Stove | Ghent University Hospital
Contact Us
Trajan Scientific Americas Inc.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Mitra® devices are intended as a specimen collector and for the storage and transport of blood. They are CE-IVD in the UK and EU, a Class 1 IVD in Australia, Brazil & China, Class B in South Africa, and registered with health agencies in Canada and Ukraine.
In the USA, Mitra devices are supplied as a Research-Use Only (RUO) product, to assist in method development, other research-related and non-diagnostic activities. Mitra has not been validated for use with any diagnostic testing. The suitability of Mitra for any analytical application must be evaluated and validated by the laboratory or research institute in a manner consistent with local regulatory requirements.
hemaPEN® is supplied for therapeutic or IVD use in Australia, New Zealand, UK, EU and USA only: ARTG number: 280007; CE mark, general IVD; US FDA number: D410490. Outside of the territories listed above, the hemaPEN is supplied for research use only (RUO) and not for therapeutic or diagnostic use.
Mitra®, VAMS® & hemaPEN® are registered trademarks owned by entities in the Trajan Group.
Copyright © 2022. All rights reserved.